Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) focuses its efforts on leveraging its proprietary technology to discover the structural secrets of complex sugars and other complex mixtures. The company’s novel approach to drug development and innovative tools have yielded a diversified product pipeline containing technology-enabled generic drugs, re-engineered drugs and novel drug candidates. Momenta’s strategic objective is to create near-term revenue opportunities that will fund longer-term discovery and development. For further information, visit the Company’s web site at www.momentapharma.com.
- 17 years ago
QualityStocks
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Tags Rodman & Renshaw
Related Post
-
Perpetuals.com Ltd. (NASDAQ: PDC) Completes BayesShield(TM) AI Pilot, Reporting 92% Block Rate on Losing Retail Crypto Trades
The BayesShield AI system analyzed a full year of real retail trading data to validate…
-
QualityStocksNewsBreaks – SPACSphere Acquisition Corp. (NASDAQ: SSACU) Closes $172.5 Million Initial Public Offering
SPACSphere Acquisition (NASDAQ: SSACU) announced the closing of its initial public offering of 17,250,000 units…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Featured by RADIO + TELEVISION BUSINESS REPORT for ADIO Engagement Platform and Real-Time Bias Meter
Datavault AI (NASDAQ: DVLT) is highlighted in the Winter 2026 issue (p. 27) of RADIO + TELEVISION BUSINESS REPORT, which examines…